Abcam, ab274431, Anti-KMT2D / MLL2 antibody [EPR20604-73] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal KMT2D / MLL2 antibody. Carrier free. Suitable for WB and reacts with Human, Recombinant fragment - Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20604-73,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab274431 is the carrier-free version of
ab213721
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The KMT2D also known as MLL2 is an important histone methyltransferase with a known mass of approximately 553 kDa. This enzyme plays a mechanical role in the methylation of histone H3 on lysine 4 (H3K4) which facilitates chromatin remodeling and transcriptional regulation. KMT2D is expressed in various tissues including the liver lungs and heart indicative of its diverse regulatory roles across different biological systems.
Biological function summary
KMT2D is an important regulatory factor that influences gene expression. It is part of a larger complex that includes other interacting proteins necessary for histone modification. Through its enzymatic activity KMT2D impacts gene transcription by modifying chromatin structure making it more or less accessible for transcription factors to bind DNA. This control over gene expression has implications in development differentiation and cellular response to external stimuli.
Pathways
KMT2D integrates into the broader framework of chromatin modification and transcriptional regulation pathways. It interacts with proteins such as ASH2L and RBBP5 which are components of the COMPASS-like complex playing roles in modifying histones to regulate gene expression dynamically. KMT2D's function intersects particularly with the Hedgehog and Wnt signaling pathways both important for developmental processes and cellular proliferation.
KMT2D has strong associations with several conditions. Mutations or dysregulation of this methyltransferase can lead to developmental disorders such as Kabuki syndrome characterized by intellectual disability and growth delays. KMT2D anomalies also appear in cancer where its dysregulation affects pathways involving the enhancer of filament genes (EFG) and histone methyltransferases like NSD2 contributing to oncogenesis by altering gene expression profiles critical for cell growth.